Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Table S1. IC50 of MPT0E028 and SAHA in pancreatic cell lines. AsPC-1, PANC-1, and BxPC-3 cells were treated with different concentrations of MPT0E028 or SAHA for 72 h. IC50 (the half maximal inhibitory concentration) was determined by MTT assay. (DOCX 12 kb)